Annexon Inc
annexonbio.comAnnexon Inc (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company developing therapies targeting classical complement-mediated autoimmune and neurodegenerative diseases. The company generates no product revenue, funding operations through equity offerings rather than commercial sales. Its pipeline includes tanruprubart, a product candidate being evaluated across multiple indications including neurodegenerative diseases such as ALS and Huntington's disease, as described in the FY2025 10-K filed March 30, 2026. Annexon raised approximately $116.8 million in net proceeds from a June 2024 equity offering and approximately $117.0 million from a December 2023 equity offering, with pre-funded warrants remaining a part of its capital structure as of the filing date. The company carries an accumulated deficit and reports net losses, with operating expenses consisting of research and development and general and administrative costs for FY2025 and FY2024. Clinical trial activity extends across jurisdictions including Australia, Canada, and New Zealand.
Products & Services
Lead product candidate: tanruprubart, targeting classical complement pathways, evaluated in neurodegenerative diseases including ALS and Huntington's disease. Pipeline focus is classical complement-mediated autoimmune and neurodegenerative diseases.
Revenue Model
Annexon has no product revenue. Operations are funded entirely through equity capital raises, including public offerings of common stock and pre-funded warrants.
Customers & Markets
No commercial customers as of the FY2025 10-K. End markets are autoimmune and neurodegenerative disease patient populations, addressed through clinical development rather than commercial sales.
Geographic Exposure
Headquartered in the United States. Clinical trials conducted across international jurisdictions including Australia, Canada, and New Zealand. Data processing involves transfers between the EEA, UK, and the United States.
Financial Snapshot
Loading...
